[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100345145":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":27,"centralContacts":31,"locations":38,"responsibleParty":57,"collaborators":26,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":26,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":26,"overallStatus":41,"whyStopped":26,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"University Hospital, Lille","OTHER",[8,13,17],{"label":9,"type":6,"description":10,"interventionNames":11},"acute alcoholic hepatitis","collection of liver biopsies collection of blood samples in patients with acute alcoholic hepatitis (group A)",[12],"Other: collection of liver biopsies collection of blood samples",{"label":14,"type":6,"description":15,"interventionNames":16},"Alcoholic cirrhosis","collection of liver biopsies collection of blood samples in patients with alcoholic cirrhosis (group B1)",[12],{"label":18,"type":6,"description":19,"interventionNames":20},"Without chronic liver disease","collection of liver biopsies collection of blood samples in patients without chronic liver disease (group B2)",[12],[22],{"type":6,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"collection of liver biopsies collection of blood samples","blood and ascites samples; extraction of explants, hepatic resection parts; hepatic parenchyma on liver biopsies",[14,18,9],null,[28],{"name":29,"affiliation":5,"role":30},"Philppe Mathurin, MD,PhD","PRINCIPAL_INVESTIGATOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Philippe Mathurin, MD,PhD","CONTACT","03 20 44 55 97","+33","philippe.mathurin@chru-lille.fr",[39],{"facility":40,"status":41,"city":42,"state":26,"zip":26,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Hôpital Claude Huriez, CHRU","RECRUITING","Lille","France","FR",{"type":46,"coordinates":47},"Point",[48,49],3.05512,50.63391,{"lat":49,"lon":48},[52,54],{"name":53,"role":30,"phone":26,"phoneExt":26,"email":26},"Philippe Mathruin, MD,PhD",{"name":55,"role":56,"phone":26,"phoneExt":26,"email":26},"Alexandre Louvet, MD,PhD","SUB_INVESTIGATOR",{"type":58,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100345145","comparison-of-inflammatory-profiles-and-regenerative-potential-in-alcoholic-liver-disease-100345145",false,"NCT03773887","Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease","TargetOH","Inclusion Criteria:\n\n* group A: patients with acute alcoholic hepatitis\n* Active alcohol abuse defined by DSM IV and excessive alcohol consumption prior to admission (\\> 60 g per day for men and\\> 40 g per day for women)\n* Moderate elevation of transaminases (less than 500 U \u002F L) with a typical ASAT \u002F ALAT ratio of 2: 1\n* Bilirubin\\> 50 mg \u002F l\n* Absence of autoimmune liver disease (ANA \\\u003C1\u002F80, AML \\\u003C1\u002F80, LKM1 neg, AAM neg)\n* Absence of hepatitis B and C and HIV infection (negative anti-HIV antibodies, negative HBsAg, negative HCV PCR)\n* Patients with other acute complications than alcoholic hepatitis may be included (eg, digestive hemorrhage, acute renal failure, infection, etc.)\n* Because there is no validated noninvasive tool for the diagnosis of alcoholic hepatitis, histological confirmation is required in all patients (preferably by transjugular biopsy): alcoholic hepatitis will be diagnosed on the presence of the following histological characteristics: Hepatocellular lesions (ballooning, Mallory body)\u002F Inflammatory infiltrate with polymorphonuclear neutrophils\n* group B1: patients with alcoholic cirrhosis\n* Decompensated or non-decompensated alcoholic cirrhosis, defined according to the HAS guidelines, ie by a liver biopsy or a cluster of clinico-biological arguments (www.has-sante.fr)\n* group B2: patients free from chronic liver disease\n* Justification of blood and liver sampling for the management of a pathology other than chronic liver disease (eg liver metastasis of digestive cancer occurring on healthy liver)\n\nExclusion Criteria:\n\n* For groups A and B1:\n* Patients with hepatocellular carcinoma of progressive non-hepatic cancer\n* Presence of HBsAg\n* Presence of anti-HCV antibodies by positive PCR\n* Presence of antibodies to HIV 1 +2\n* Pregnancy\n* for group B2:\n* Alcoholic liver disease\n* Presence of HBsAg\n* Presence of anti-HCV antibodies by positive PCR\n* Presence of antibodies to HIV 1 +2\n* Pregnancy","ALL","18 Years","70 Years",{"count":70,"type":71},450,"ESTIMATED","INTERVENTIONAL",[74],"NA","The main objective of this study is the comparison of the profile of the pro-inflammatory cytokines at the patients suffering from an alcoholic hepatitis to that of two groups witnesses: patients suffering from an alcoholic cirrhosis and unhurt patients of chronic liver disease",[77,78],"Liver Diseases","Acute on Chronic Hepatic Failure","2026-05-20",{"date":81,"type":82},"2026-05-22","ACTUAL",{"date":84,"type":82},"2014-12-25",{"date":86,"type":71},"2027-09",{"name":5,"class":6},1]